fca4c327-dfab-4455-84a8-f890a7326132
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.570
- MYC_TARGETS_V1+0.540
- INTERFERON_GAMMA_RESPONSE+0.530
- E2F_TARGETS+0.510
- TNFA_SIGNALING_VIA_NFKB+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.490
- G2M_CHECKPOINT+0.480
- MTORC1_SIGNALING+0.480
- ALLOGRAFT_REJECTION+0.460
- IL6_JAK_STAT3_SIGNALING+0.430
Top 10 suppressed
- BILE_ACID_METABOLISM-0.340
- HEDGEHOG_SIGNALING-0.280
- KRAS_SIGNALING_DN-0.260
- WNT_BETA_CATENIN_SIGNALING-0.240
- MYOGENESIS-0.190
- ESTROGEN_RESPONSE_EARLY-0.180
- FATTY_ACID_METABOLISM-0.100
- ESTROGEN_RESPONSE_LATE-0.070
- XENOBIOTIC_METABOLISM-0.070
- UV_RESPONSE_DN-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | CA6E11F4-8B85-4C73-9B48-C28F5D5D91D6 | — | — | 0.936 |
| 2 | A43D720D-0CA3-48CF-ADC7-5AC72BD5EEA9 | — | — | 0.931 |
| 3 | SRR1516056 | — | — | 0.930 |
| 4 | SRR934888 | — | — | 0.924 |
| 5 | 8B4E465B-0FD5-4154-824B-1E6B2656FD2F | — | — | 0.921 |
| 6 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.920 |
| 7 | BS_KE56MMY0 | Neurofibroma | — | 0.918 |
| 8 | 3E499D12-B08A-491C-98C6-19EA420BDC99 | — | — | 0.918 |
| 9 | 91E04630-B2A7-448E-8C80-580818C9D7E6 | — | — | 0.917 |
| 10 | TCGA-IQ-A61E-01A-22R-A30B-07 | — | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.490 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |